CASI Pharmaceuticals (FRA:ENM) Institutional Ownership: 0.09% (As of Jul. 22, 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

FRA:ENM CASI Pharmaceuticals Inc FRA:ENM
29 GF Score
Price €1.54
GF Value €10.30
! 5 Warning Signs
View Full Analysis

What is CASI Pharmaceuticals Institutional Ownership?

CASI Pharmaceuticals FRA:ENM 29 Institutional Ownership is 0.09% as of Jul. 22, 2026. GuruFocus rates FRA:ENM with a GF Score™ of 29/100 and a GF Value™ of €10.30. The stock has 5 warning signs investors should review.

Institutional ownership is the percentage of shares that are owned by institutions out of the total shares outstanding. As of today, CASI Pharmaceuticals's institutional ownership is 0.09%.

Insider Ownership is the percentage of shares that are owned by company insiders relative to the total shares outstanding. As of today, CASI Pharmaceuticals's Insider Ownership is 0.00%.

Float Percentage Of Total Shares Outstanding is the percentage of float shares relative to the total shares outstanding. As of today, CASI Pharmaceuticals's Float Percentage Of Total Shares Outstanding is 21.21%.

CASI Pharmaceuticals Institutional Ownership Historical Data

* Premium members only.

The historical data trend for CASI Pharmaceuticals's Institutional Ownership can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

CASI Pharmaceuticals Institutional Ownership Chart

CASI Pharmaceuticals Historical Data

The historical data trend for CASI Pharmaceuticals can be seen below:

2025-03-31 2025-04-30 2025-05-31 2025-06-30 2025-07-31 2025-08-31 2025-09-30 2025-10-31 2025-12-31 2026-01-31
Institutional Ownership 0.15 0.14 0.14 0.14 0.14 0.14 0.09 0.09 0.09 0.09
FRA:ENM
29GF Score
CASI Pharmaceuticals Inc FRA:ENM
Institutional Ownership is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

CASI Pharmaceuticals Institutional Ownership Calculation

The percentage of shares that are owned by institutions out of the total shares outstanding.

What does a Institutional Ownership of 0.09% mean?
CASI Pharmaceuticals (FRA:ENM) has a Institutional Ownership of 0.09% as of Jul. 22, 2026. Institutional ownership equals the percent of shares owned by financial institutions relative to total shares. View historical data on CASI Pharmaceuticals and its competitors.
Is CASI Pharmaceuticals' Institutional Ownership too high?
CASI Pharmaceuticals' current Institutional Ownership is 0.09%. Overall, CASI Pharmaceuticals has a GF Score™ of 29/100, reflecting its overall financial health beyond just this single metric.
How does CASI Pharmaceuticals' Institutional Ownership compare to ITRMF and OGEN?
CASI Pharmaceuticals' Institutional Ownership of 0.09% can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Institutional Ownership for a Biotechnology company?
A good Institutional Ownership depends on the Biotechnology industry context. However, Institutional Ownership should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Institutional Ownership mean?
A high Institutional Ownership can signal that a stock is expensive relative to its fundamentals. Institutional ownership equals the percent of shares owned by financial institutions relative to total shares. View historical data on CASI Pharmaceuticals and its competitors. CASI Pharmaceuticals's current Institutional Ownership is 0.09%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is CASI Pharmaceuticals stock overvalued right now?
CASI Pharmaceuticals (FRA:ENM) has a current Institutional Ownership of 0.09%. The stock's GF Value™ is €10.30, compared to a current price of €1.54 — trading 85% below its estimated fair value. The current Institutional Ownership is 0.09%. CASI Pharmaceuticals' overall GF Score™ is 29/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Institutional Ownership calculated?
Institutional Ownership is calculated from a company's financial statements. For CASI Pharmaceuticals (FRA:ENM), the current Institutional Ownership is 0.09% as of Jul. 22, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is CASI Pharmaceuticals (FRA:ENM) Overvalued in 2026?

Based on GuruFocus' analysis, CASI Pharmaceuticals stock appears to be undervalued. The current stock price of €1.54 is trading 85% below its estimated GF Value™ of €10.30.

Key valuation signals for FRA:ENM:

  • Institutional Ownership: 0.09%
  • GF Value™: €10.30 vs. price of €1.54 (85% below fair value)
  • GF Score™: 29/100 with 5 warning signs

No single metric tells the full story. See the FRA:ENM stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

CASI Pharmaceuticals Business Description

Other Exchanges CASIF:USA
Address Jianguo Road, No. 81, Room 1701-1702, China Central Office Tower 1, Huamao Office Building, Chaoyang District, Beijing, CHN, 100025
CASI Pharmaceuticals Inc is a clinical-stage biopharmaceutical company developing CID-103, an anti-CD38 monoclonal antibody, for patients with organ transplant rejection and autoimmune diseases. Additionally, the company manages its other assets, including EVOMELA, FOLOTYN, CNCT19, BI-1206, and CB-5339, with a primary strategic emphasis on advancing CID-103 toward key clinical and regulatory milestones. It also distributes YuTuo (Zimberelimab), a fully human anti-PD-1 monoclonal antibody for patients with relapsed or refractory classical Hodgkin's lymphoma and recurrent or metastatic cervical cancer. Geographically, the company's revenue is solely generated in Mainland China.
29GF Score

Get the complete analysis for FRA:ENM

Institutional Ownership is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€1.54
Price
€10.30
GF Value